Incyte Corporation (INCY) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
Total Assets Chart for Incyte Corporation
Incyte Corporation (INCY) total assets for FY2025 were USD 7.0B, a 27.8% change from FY2024. Incyte Corporation's total assets grew from USD 17.6M in 1993 to USD 7.0B in 2025 (39433.9% over 32 years). Total assets compound annual growth rate: 5-year CAGR of 14.3%, 10-year CAGR of 21.3%, 20-year CAGR of 15.7%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $24.00B
- Implied Share Price
- $118.38
- Enterprise Value
- $19.95B
- Revenue (TTM)
- $5.82B
- EBITDA
- $1.94B
- Profit Margin
- 27.71%
- Trailing P/E
- 15.27
- Forward P/E
- 38.76
- Price/Book (MRQ)
- 3.85
- Price/Sales (TTM)
- 4.12
- EV/EBITDA
- 9.65
- EV/Revenue
- 3.43
- Dividend Yield
- —
- Book Value
- $31.57
- Free Cash Flow (FY2025)
- $1.35B
- Free Cash Flow Yield
- 5.65%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.